CHARLES RIVER LABORATORIES INTERNA (CRL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CRL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CRL | Executive Vice President and Chief Commercial Officer, Novartis US | 53 | ["extensive healthcare business leadership knowledge", "deep industry experience at two of the top-10 global pharmaceutical companies", "demonstrated ability to oversee large commercial organizations across multiple therapeutic areas", "sales and marketing expertise", "over 25 years of experience in the life-sciences sector"] | ["Rutgers Cancer Institute Leadership Council", "Healthcare Businesswomen\u2019s Association (HBA) Global Advisory Board", "CEO Roundtable on Cancer"] | 2026 |
Biography sourced from the proxy statement filing.
Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company Novartis AG, responsible for end-to-end commercialization across four therapeutic areas. Ms. Kemps-Polanco returned to Novartis in 2021 as EVP & US Head, Novartis Oncology. Prior to rejoining Novartis, Ms. Kemps-Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Ms. Kemps-Polanco began her pharmaceutical industry career at Novartis in 2012 in sales and held management positions of increasing responsibility. Ms. Kemps-Polanco is a member of the Rutgers Cancer Institute Leadership Council, the Healthcare Businesswomen s Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps-Polanco has been a board member since January 2024. Ms. Kemps-Polanco was selected for the Board in recognition of her distinct perspective due to her extensive healthcare business leadership knowledge, her deep industry experience at two of the top-10 global pharmaceutical companies, her demonstrated ability to oversee large commercial organizations across multiple therapeutic areas, including sales and marketing expertise, as well as her over 25 years of experience in the life-sciences sector.